Copyright Reports & Markets. All rights reserved.

Global Mitochondrial-based Therapeutics Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope of Mitochondrial-based Therapeutics
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Mitochondrial-based Therapeutics by Type
    • 1.3.1 Overview: Global Mitochondrial-based Therapeutics Market Size by Type: 2018 Versus 2022 Versus 2029
    • 1.3.2 Global Mitochondrial-based Therapeutics Consumption Value Market Share by Type in 2022
    • 1.3.3 Oral
    • 1.3.4 Intravenous
  • 1.4 Global Mitochondrial-based Therapeutics Market by Application
    • 1.4.1 Overview: Global Mitochondrial-based Therapeutics Market Size by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 Mitochondrial Myopathy
    • 1.4.3 Leber’s heredity Optic Neuropathy
    • 1.4.4 Leigh Syndrome
    • 1.4.5 Mitochondrial DNA Depletion Syndrome
    • 1.4.6 Other
  • 1.5 Global Mitochondrial-based Therapeutics Market Size & Forecast
  • 1.6 Global Mitochondrial-based Therapeutics Market Size and Forecast by Region
    • 1.6.1 Global Mitochondrial-based Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
    • 1.6.2 Global Mitochondrial-based Therapeutics Market Size by Region, (2018-2029)
    • 1.6.3 North America Mitochondrial-based Therapeutics Market Size and Prospect (2018-2029)
    • 1.6.4 Europe Mitochondrial-based Therapeutics Market Size and Prospect (2018-2029)
    • 1.6.5 Asia-Pacific Mitochondrial-based Therapeutics Market Size and Prospect (2018-2029)
    • 1.6.6 South America Mitochondrial-based Therapeutics Market Size and Prospect (2018-2029)
    • 1.6.7 Middle East and Africa Mitochondrial-based Therapeutics Market Size and Prospect (2018-2029)

2 Company Profiles

  • 2.1 Reneo Pharmaceutical
    • 2.1.1 Reneo Pharmaceutical Details
    • 2.1.2 Reneo Pharmaceutical Major Business
    • 2.1.3 Reneo Pharmaceutical Mitochondrial-based Therapeutics Product and Solutions
    • 2.1.4 Reneo Pharmaceutical Mitochondrial-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 Reneo Pharmaceutical Recent Developments and Future Plans
  • 2.2 Pfizer Inc.
    • 2.2.1 Pfizer Inc. Details
    • 2.2.2 Pfizer Inc. Major Business
    • 2.2.3 Pfizer Inc. Mitochondrial-based Therapeutics Product and Solutions
    • 2.2.4 Pfizer Inc. Mitochondrial-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 Pfizer Inc. Recent Developments and Future Plans
  • 2.3 Norvartis AG
    • 2.3.1 Norvartis AG Details
    • 2.3.2 Norvartis AG Major Business
    • 2.3.3 Norvartis AG Mitochondrial-based Therapeutics Product and Solutions
    • 2.3.4 Norvartis AG Mitochondrial-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 Norvartis AG Recent Developments and Future Plans
  • 2.4 Takeda Pharmaceuticals
    • 2.4.1 Takeda Pharmaceuticals Details
    • 2.4.2 Takeda Pharmaceuticals Major Business
    • 2.4.3 Takeda Pharmaceuticals Mitochondrial-based Therapeutics Product and Solutions
    • 2.4.4 Takeda Pharmaceuticals Mitochondrial-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 Takeda Pharmaceuticals Recent Developments and Future Plans
  • 2.5 Amgen Inc.
    • 2.5.1 Amgen Inc. Details
    • 2.5.2 Amgen Inc. Major Business
    • 2.5.3 Amgen Inc. Mitochondrial-based Therapeutics Product and Solutions
    • 2.5.4 Amgen Inc. Mitochondrial-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 Amgen Inc. Recent Developments and Future Plans
  • 2.6 NeuroVive Pharmaceutical AB
    • 2.6.1 NeuroVive Pharmaceutical AB Details
    • 2.6.2 NeuroVive Pharmaceutical AB Major Business
    • 2.6.3 NeuroVive Pharmaceutical AB Mitochondrial-based Therapeutics Product and Solutions
    • 2.6.4 NeuroVive Pharmaceutical AB Mitochondrial-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 NeuroVive Pharmaceutical AB Recent Developments and Future Plans
  • 2.7 Entogene AG
    • 2.7.1 Entogene AG Details
    • 2.7.2 Entogene AG Major Business
    • 2.7.3 Entogene AG Mitochondrial-based Therapeutics Product and Solutions
    • 2.7.4 Entogene AG Mitochondrial-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.7.5 Entogene AG Recent Developments and Future Plans
  • 2.8 Stealth Biotherapeutics
    • 2.8.1 Stealth Biotherapeutics Details
    • 2.8.2 Stealth Biotherapeutics Major Business
    • 2.8.3 Stealth Biotherapeutics Mitochondrial-based Therapeutics Product and Solutions
    • 2.8.4 Stealth Biotherapeutics Mitochondrial-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.8.5 Stealth Biotherapeutics Recent Developments and Future Plans
  • 2.9 Ixchel Pharma
    • 2.9.1 Ixchel Pharma Details
    • 2.9.2 Ixchel Pharma Major Business
    • 2.9.3 Ixchel Pharma Mitochondrial-based Therapeutics Product and Solutions
    • 2.9.4 Ixchel Pharma Mitochondrial-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.9.5 Ixchel Pharma Recent Developments and Future Plans
  • 2.10 Reata Pharmaceuticals
    • 2.10.1 Reata Pharmaceuticals Details
    • 2.10.2 Reata Pharmaceuticals Major Business
    • 2.10.3 Reata Pharmaceuticals Mitochondrial-based Therapeutics Product and Solutions
    • 2.10.4 Reata Pharmaceuticals Mitochondrial-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.10.5 Reata Pharmaceuticals Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Mitochondrial-based Therapeutics Revenue and Share by Players (2018-2023)
  • 3.2 Market Share Analysis (2022)
    • 3.2.1 Market Share of Mitochondrial-based Therapeutics by Company Revenue
    • 3.2.2 Top 3 Mitochondrial-based Therapeutics Players Market Share in 2022
    • 3.2.3 Top 6 Mitochondrial-based Therapeutics Players Market Share in 2022
  • 3.3 Mitochondrial-based Therapeutics Market: Overall Company Footprint Analysis
    • 3.3.1 Mitochondrial-based Therapeutics Market: Region Footprint
    • 3.3.2 Mitochondrial-based Therapeutics Market: Company Product Type Footprint
    • 3.3.3 Mitochondrial-based Therapeutics Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Mitochondrial-based Therapeutics Consumption Value and Market Share by Type (2018-2023)
  • 4.2 Global Mitochondrial-based Therapeutics Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

  • 5.1 Global Mitochondrial-based Therapeutics Consumption Value Market Share by Application (2018-2023)
  • 5.2 Global Mitochondrial-based Therapeutics Market Forecast by Application (2024-2029)

6 North America

  • 6.1 North America Mitochondrial-based Therapeutics Consumption Value by Type (2018-2029)
  • 6.2 North America Mitochondrial-based Therapeutics Consumption Value by Application (2018-2029)
  • 6.3 North America Mitochondrial-based Therapeutics Market Size by Country
    • 6.3.1 North America Mitochondrial-based Therapeutics Consumption Value by Country (2018-2029)
    • 6.3.2 United States Mitochondrial-based Therapeutics Market Size and Forecast (2018-2029)
    • 6.3.3 Canada Mitochondrial-based Therapeutics Market Size and Forecast (2018-2029)
    • 6.3.4 Mexico Mitochondrial-based Therapeutics Market Size and Forecast (2018-2029)

7 Europe

  • 7.1 Europe Mitochondrial-based Therapeutics Consumption Value by Type (2018-2029)
  • 7.2 Europe Mitochondrial-based Therapeutics Consumption Value by Application (2018-2029)
  • 7.3 Europe Mitochondrial-based Therapeutics Market Size by Country
    • 7.3.1 Europe Mitochondrial-based Therapeutics Consumption Value by Country (2018-2029)
    • 7.3.2 Germany Mitochondrial-based Therapeutics Market Size and Forecast (2018-2029)
    • 7.3.3 France Mitochondrial-based Therapeutics Market Size and Forecast (2018-2029)
    • 7.3.4 United Kingdom Mitochondrial-based Therapeutics Market Size and Forecast (2018-2029)
    • 7.3.5 Russia Mitochondrial-based Therapeutics Market Size and Forecast (2018-2029)
    • 7.3.6 Italy Mitochondrial-based Therapeutics Market Size and Forecast (2018-2029)

8 Asia-Pacific

  • 8.1 Asia-Pacific Mitochondrial-based Therapeutics Consumption Value by Type (2018-2029)
  • 8.2 Asia-Pacific Mitochondrial-based Therapeutics Consumption Value by Application (2018-2029)
  • 8.3 Asia-Pacific Mitochondrial-based Therapeutics Market Size by Region
    • 8.3.1 Asia-Pacific Mitochondrial-based Therapeutics Consumption Value by Region (2018-2029)
    • 8.3.2 China Mitochondrial-based Therapeutics Market Size and Forecast (2018-2029)
    • 8.3.3 Japan Mitochondrial-based Therapeutics Market Size and Forecast (2018-2029)
    • 8.3.4 South Korea Mitochondrial-based Therapeutics Market Size and Forecast (2018-2029)
    • 8.3.5 India Mitochondrial-based Therapeutics Market Size and Forecast (2018-2029)
    • 8.3.6 Southeast Asia Mitochondrial-based Therapeutics Market Size and Forecast (2018-2029)
    • 8.3.7 Australia Mitochondrial-based Therapeutics Market Size and Forecast (2018-2029)

9 South America

  • 9.1 South America Mitochondrial-based Therapeutics Consumption Value by Type (2018-2029)
  • 9.2 South America Mitochondrial-based Therapeutics Consumption Value by Application (2018-2029)
  • 9.3 South America Mitochondrial-based Therapeutics Market Size by Country
    • 9.3.1 South America Mitochondrial-based Therapeutics Consumption Value by Country (2018-2029)
    • 9.3.2 Brazil Mitochondrial-based Therapeutics Market Size and Forecast (2018-2029)
    • 9.3.3 Argentina Mitochondrial-based Therapeutics Market Size and Forecast (2018-2029)

10 Middle East & Africa

  • 10.1 Middle East & Africa Mitochondrial-based Therapeutics Consumption Value by Type (2018-2029)
  • 10.2 Middle East & Africa Mitochondrial-based Therapeutics Consumption Value by Application (2018-2029)
  • 10.3 Middle East & Africa Mitochondrial-based Therapeutics Market Size by Country
    • 10.3.1 Middle East & Africa Mitochondrial-based Therapeutics Consumption Value by Country (2018-2029)
    • 10.3.2 Turkey Mitochondrial-based Therapeutics Market Size and Forecast (2018-2029)
    • 10.3.3 Saudi Arabia Mitochondrial-based Therapeutics Market Size and Forecast (2018-2029)
    • 10.3.4 UAE Mitochondrial-based Therapeutics Market Size and Forecast (2018-2029)

11 Market Dynamics

  • 11.1 Mitochondrial-based Therapeutics Market Drivers
  • 11.2 Mitochondrial-based Therapeutics Market Restraints
  • 11.3 Mitochondrial-based Therapeutics Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry
  • 11.5 Influence of COVID-19 and Russia-Ukraine War
    • 11.5.1 Influence of COVID-19
    • 11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis

  • 12.1 Mitochondrial-based Therapeutics Industry Chain
  • 12.2 Mitochondrial-based Therapeutics Upstream Analysis
  • 12.3 Mitochondrial-based Therapeutics Midstream Analysis
  • 12.4 Mitochondrial-based Therapeutics Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Mitochondrial-based Therapeutics market size was valued at USD 390 million in 2022 and is forecast to a readjusted size of USD 645.5 million by 2029 with a CAGR of 7.5% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
    Mitochondria are therefore vital for normal cellular function, including intracellular metabolic activities and signal transduction of various cellular pathways. They are involved in cellular ion homeostasis, oxidative stress, and apoptotic and necrotic cell death.
    This report is a detailed and comprehensive analysis for global Mitochondrial-based Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
    Key Features:
    Global Mitochondrial-based Therapeutics market size and forecasts, in consumption value ($ Million), 2018-2029
    Global Mitochondrial-based Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
    Global Mitochondrial-based Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
    Global Mitochondrial-based Therapeutics market shares of main players, in revenue ($ Million), 2018-2023
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Mitochondrial-based Therapeutics
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Mitochondrial-based Therapeutics market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Reneo Pharmaceutical, Pfizer Inc., Norvartis AG, Takeda Pharmaceuticals and Amgen Inc., etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
    Market segmentation
    Mitochondrial-based Therapeutics market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Oral
    Intravenous
    Market segment by Application
    Mitochondrial Myopathy
    Leber’s heredity Optic Neuropathy
    Leigh Syndrome
    Mitochondrial DNA Depletion Syndrome
    Other
    Market segment by players, this report covers
    Reneo Pharmaceutical
    Pfizer Inc.
    Norvartis AG
    Takeda Pharmaceuticals
    Amgen Inc.
    NeuroVive Pharmaceutical AB
    Entogene AG
    Stealth Biotherapeutics
    Ixchel Pharma
    Reata Pharmaceuticals
    Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Mitochondrial-based Therapeutics product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Mitochondrial-based Therapeutics, with revenue, gross margin and global market share of Mitochondrial-based Therapeutics from 2018 to 2023.
    Chapter 3, the Mitochondrial-based Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Mitochondrial-based Therapeutics market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
    Chapter 12, the key raw materials and key suppliers, and industry chain of Mitochondrial-based Therapeutics.
    Chapter 13, to describe Mitochondrial-based Therapeutics research findings and conclusion.

    Buy now